Craft

Collegium Pharmaceutical

Stock Price

$35.2

2024-10-29

Market Capitalization

$1.1 B

2024-10-29

Revenue

$780.6 M

FY, 2025

Collegium Pharmaceutical Summary

Company Summary

Overview
Collegium Pharmaceutical is a company that develops and provides medicines for pain management and attention deficit hyperactivity disorder. Its products include Xtampza ER, an extended-release formulation of oxycodone; Belbuca, a buccal film with buprenorphine; Jornay PM, a central nervous system stimulant for ADHD; Nucynta in extended-release and immediate-release forms; and Symproic for opioid-induced constipation. The company serves individuals with pain conditions, ADHD, and prescribers in the United States.
Type
Public
Status
Active
Founded
2002
HQ
Stoughton, MA, US | view all locations
Website
https://www.collegiumpharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Michael Heffernan

    Michael Heffernan, Interim President and Chief Executive Officer, Founder and Chairman of the Board

  • Colleen Tupper

    Colleen Tupper, Chief Financial Officer

  • Scott Dreyer

    Scott Dreyer, Chief Commercial Officer

  • Shirley Kuhlmann

    Shirley Kuhlmann, General Counsel and Chief Administrative Officer

LocationsView all

1 location detected

  • Stoughton, MA HQ

    United States

    100 Technology Center Dr #300

Collegium Pharmaceutical Financials

Summary Financials

Revenue (Q1, 2026)
$193.5M
Gross profit (Q1, 2026)
$117.2M
Net income (Q1, 2026)
$14.5M
Cash (Q1, 2026)
$268.6M
EBIT (Q1, 2026)
$30.9M
Enterprise value
$1.7B

Footer menu